EP0777481A1

EP0777481A1 - Use of n-substituted phenothiazines

Info

Publication number: EP0777481A1
Application number: EP95929864A
Authority: EP
Inventors: Klaus Urbahns; Hans-Georg Heine; Bodo Junge; Rudolf Schohe-Loop; Henning Sommermeyer; Thomas Glaser; Reilinde Wittka; Jean-Marie-Viktor De Vry
Original assignee: Bayer AG
Current assignee: Bayer AG
Priority date: 1994-08-25
Filing date: 1995-08-14
Publication date: 1997-06-11
Also published as: JPH10504820A; DE4430091A1; ZA957113B; WO1996005837A1; IL115027A; AU3345395A; MY132077A; IL115027A0; US5861394A; CA2198256A1; TW408117B

Abstract

The invention concerns the use of N-substituted phenothiazines for producing drugs for treating cerebral disorders. The invention also concerns novel active substances prepared by reacting phenothiazine with the appropriate acids, esters or amides or by reacting phenothiazine carboxylic acid halides with amines. The active substances are in particular suitable for treating dementia, depression and learning and memory disorders caused by old age.

Description

Use of N-substituted phenothiazines

The present invention relates to the use of N-substituted phenothiazines for the production of medicaments, new active ingredients, a process for their preparation, in particular the use as a cerebrally active agent.

It is already known that 10-carboxamide-substituted phenothiazines have an anti-tumor effect [cf. JP 561 66 183 A2, 1981]. The publication US Pat. No. 4,833,138 also describes phenothiazine derivatives for the treatment of neurotoxic diseases. Furthermore, in the publication [Arch. Int. Pharmacodyn. Ther. 173 (1), 44-55, (1968)] Effects of some phenothiazines listed in the intrapleural fluid test.

It has now been found that N-substituted phenothiazines of the general formula (I).

in which

R ^{1 represents} a radical of the formula - (CH ₂ ) _a -CO-R ⁶ , - (CH ₂ ) _a -CO-NR ⁷ R ⁸ or - (CH ₂ ) _b -R ⁹ ,

woπn

a represents a number 0, 1 or 2,

b represents a number 1 or 2, R ⁶ denotes hydrogen or straight-chain or branched alkoxy or alkyl each having up to 6 carbon atoms, the latter being able to be substituted by halogen or hydroxy,

R ^{7 is} hydrogen or straight-chain or branched alkyl with up to 6

Means carbon atoms which is optionally substituted by halogen,

R ^{8 is} hydrogen, cycloalkyl with 3 to 6 carbon atoms, pyridyl, phenyl, amino or straight-chain or branched alkyl with up to

6 carbon atoms, which is optionally substituted by hydroxy or pyridyl,

or

R ⁷ and R ⁸ together with the nitrogen atom form a piperidine, morpholine, azacycloheptyl or pyrrolidinyl ring,

R ⁹ denotes cyano or straight-chain or branched alkoxycarbonyl having up to 6 carbon atoms,

R ² , R ³ , R ⁴ and R ^{5 are} identical or different and represent hydrogen, halogen or trifluoromethyl,

and their salts surprisingly have a modulating effect on potassium channels and are therefore suitable for use in combating diseases of the central nervous system (CNS) and of the sick cell anemia.

Physiologically acceptable salts are preferred in the context of the invention.

Physiologically acceptable salts are generally salts of the compounds according to the invention with inorganic or organic acids. Salts with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid or sulfuric acid are preferred, or salts with organic carboxylic or sulfonic acids such as acetic acid, maleic acid, fumaric acid. acid, malic acid, citric acid, tartaric acid, lactic acid, benzoic acid, or methanesulfonic acid, ethanesulfonic acid, phenylsulfonic acid, toluenesulfonic acid or naphthalenedisulfonic acid.

The compounds according to the invention can exist in stereoisomeric forms which either behave like image and mirror image (enantiomers) or which do not behave like image and mirror image (diastereomers). The invention relates to both the antipodes and the racemic forms as well as the diastereomer mixtures. Like the diastereomers, the racemic forms can be separated into the stereoisomerically uniform constituents in a known manner.

Compounds of the general formula (I) are preferred

in which

wherein

a represents a number 0, 1 or 2,

b represents a number 1 or 2,

R ⁶ denotes hydrogen or straight-chain or branched alkoxy or alkyl each having up to 4 carbon atoms, the latter being able to be substituted by fluorine, chlorine or hydroxy,

R ⁷ denotes hydrogen or straight-chain or branched alkyl having up to 4 carbon atoms, which is optionally substituted by chlorine,

R ^{8 is} hydrogen, pyridyl, phenyl, amino, cyclopropyl, cyclopentyl, cyclohexyl or straight-chain or branched alkyl with up to 4 Means carbon atoms which is optionally substituted by hydroxy or pyridyl,

or

R ⁹ denotes cyano or straight-chain or branched alkoxycarbonyl having up to 4 carbon atoms,

R ² and R ^{5 are the} same or different and represent hydrogen, fluorine, chlorine, bromine or trifluoromethyl,

R ³ and R ^{4 represent} hydrogen,

and their salts,

in combating diseases of the CNS.

Compounds of the general formula (I) are particularly preferred

in which

wherein

a represents a number 0, 1 or 2,

b represents a number 1 or 2, R ⁶ denotes hydrogen or straight-chain or branched alkoxy or alkyl each having up to 4 carbon atoms, the latter being able to be substituted by fluorine, chlorine or hydroxy,

R ^{7 is} hydrogen or straight-chain or branched alkyl with up to 4

Means carbon atoms which is optionally substituted by chlorine,

R ^{8 is} hydrogen, pyridyl, phenyl, amino, cyclopropyl, cyclopentyl, cyclohexyl or straight-chain or branched alkyl with up to 4

Means carbon atoms which is optionally substituted by hydroxy or pyridyl,

or

R ³ and R ^{4 represent} hydrogen,

and their salts,

in combating diseases of the CNS.

The compounds of general formula (I) according to the invention show an unforeseeable, valuable pharmacological spectrum of action.

They are channel modulators with selectivity for calcium-dependent potassium channels of high conductivity (BK (Ca) channels), especially of the central nervous system. Due to their pharmacological properties, they can be used in the manufacture of medicinal products for the treatment of central degenerative diseases, such as, for example, when dementias such as multi-infarct dementia (MID), primarily degenerative dementia (PDD), presence and senile dementia of the type of Alzheimer's disease, HIV dementia and others

Dementia forms. They are also suitable for the treatment of Parkinson's disease or amyotrophic lateral sclerosis and multiple sclerosis.

The active ingredients are also suitable for the treatment of brain performance disorders in old age, organic brain psychosyndrome (HOPS, Organic Brain Syndrome, OBS) and age-related memory disorders (AAMI).

They are suitable for prophylaxis, treatment and combating the consequences of cerebral circulatory disorders such as cerebral ischemia, strokes,

Traumatic brain injury and subarachnoid hemorrhage.

They are valuable for the treatment of depression and psychoses, e.g. Schizophrenia. They are also suitable for the treatment of disorders of neuroendocrine secretion and of neurotransmitter secretion and related health disorders such as mania, alcoholism, drug abuse, addiction or pathological eating behavior. Other areas of application are the treatment of migraines, sleep disorders and neuropathies. They are also suitable as pain relievers.

The active compounds are also suitable for treating disorders of the immune system, in particular T lymphocyte proliferation and for influencing smooth muscles, in particular the uterus, urinary bladder and bronchial tract and for treating related diseases such as e.g. Asthma and urinary incontinence and used to treat hypertension, arrhythmia, angina and diabetes.

The invention also relates to new compounds of the general formula (Ia) and their salts

with the substituent meanings given in the following table:

R ¹ R ²

-CO-N (CH ₃ ) -C ₆ H ₅ H

-CO- (CH ₂ ) ₃ -Cl Cl

-CO- (CH ₂ ) ₃ -Cl H

-CO-N ((CH ₂ ) ₃ CH ₃ ) ₂ H

-CO-N (CH ₃ ) -C ₆ H _π H

- (CH ₂ ) ₂ -CO-NH-C ₂ H ₅ Cl

- (CH ₂ ) ₂ -CO-NH (CH ₂ ) ₃ -CH ₃ Cl

- (CH ₂ ) ₂ -CO-NH- (CH ₂ ) ₃ -CH ₃ H

- (CH ₂ ) ₂ -CO-NH- (CH ₂ ) ₂ CH ₃ H

- (CH ₂ ) -CO-N (CH ₂ CH ₃ ) ₂ H

R ¹ R ²

H

-CO-N

-CH ₂ -CO-NH- (CH ₂ ) ₃ CH ₃ H

-CH ₂ -CO-NH- (CH ₂ ) ₂ CH ₃ H -CH ₂ -CO-NH-C ₂ H ₅ H

-CH ₂ -CO-NH ((CH ₂ ) ₂ CH ₃ ) ₂ H

The compounds of general formula (I) according to the invention are prepared by:

either directly phenothiazine with the corresponding acids, esters or amides of the general formula (II)

ER ¹ (H.)

in which

E represents a typical leaving group, such as chlorine or iodine, preferably chlorine,

in inert solvents and in the presence of a base, if appropriate under an inert gas atmosphere

or in the case of the amides - (CH ₂ ) _a -CO-NR ⁷ R ⁸ starting from the corresponding acid chlorides of the general formula (Ib)

in which CO-CI

R to R and a have the meaning given,

with amines of the general formula (HI)

H-NR ⁷ R ⁸ (HI)

in which

R ⁷ and R ^{8 have} the specified scope,

in inert solvents, if appropriate in the presence of a further base and if appropriate under a protective gas atmosphere.

The process according to the invention can be illustrated by the following formula scheme:

All inert organic solvents which do not change under the reaction conditions are suitable as solvents. These preferably include alcohols such as methanol, ethanol, propanol or isopropanol, or ethers such as diethyl ether, dioxane, tetrahydrofuran, glycol dimethyl ether, or diethylene glycol dimethyl ether, acetonitrile, or amides such as hexamethylphosphoric triamide or dimethylformamide, or halogenated hydrocarbons such as methylene chloride or hydrocarbons such as benzene Toluene. It is also possible to use mixtures of the solvents mentioned. Dimethylformamide is particularly preferred.

Suitable bases are generally alkali metal hydrides or alcoholates, such as sodium hydride or potassium tert-butoxide, or cyclic amines such as piperidine, dimethylaminopyridine or C _j -C ₄ alkylamines, such as triethylamine. Triethylamine and sodium hydride are preferred depending on the respective reaction steps.

When carrying out the process according to the invention, the ratio of the substances involved in the reaction is arbitrary. In general, however, one works with molar amounts of the reactants.

The reaction temperatures can be varied over a wide range. In general, between -10 ° C and + 150 ° C, preferably between 0 ° C and + 100 ° C, especially at the boiling point of the solvent. The reactions can be carried out at normal pressure, but also at elevated or reduced pressure (for example 0.5 to 3 bar). Generally one works at normal pressure.

For some reaction steps, the reaction under an inert gas atmosphere is appropriate.

The customary reagents such as inorganic halides, for example thionyl chloride, phosphorus trichloride or phosphorus pentachloride, or carbonyldiimidazole, carbodiimides such as cyclohexylcarbodiimide or 1-cyclohexyl-3- [2- (N-methylmo holino) ethyl] carbodiimide are suitable for activating the carboxylic acid -p- toluenesulfonate or N-hydroxyphthalimide or N-hydroxy-benzotriazole.

The enantiomerically pure compounds can also be obtained by chromatography of the racemic esters on chiral phases.

The compounds of the general formulas (II) and (HI) are known.

Some of the phenothiazine-10-carboxylic acid chlorides of the general formula (Ia) are known or new and can then be prepared, for example, as described above by reacting phenothiazine with the corresponding acid chlorides.

Nomenclature names phenothiazine-10-carboxylic acid-NN-di-n-propylaήιid are known (US 4,833,138); Nomiglaturname 3- (Phenothiazin-10-yl) methyl propynate

(WO 9 412 621; WO 9 412 619) and nomenclature name 3- (2-chlorophenthiazin- 10-yl) propionic acid methyl ester (US 2,820,031 (1953)).

^ Rubidium efflux from C6-BUl glioma cells

The experiments were carried out with minor changes in accordance with that of Tas et al. (Neurosci. Lett. 94, 279-284, (1988)). Rats C6-BU1 glioma cells are used for this.

From the data obtained by liquid scintillation, the increase in Rb efflux caused by ionomycin above basal flow is calculated and set as 100%. The stimulations in the presence of test substances are then related to this value.

The present invention also includes pharmaceutical preparations which, in addition to inert, non-toxic, pharmaceutically suitable auxiliaries and excipients, contain one or more compounds of the general formulas (I) / (Ia) / (Ib) or which consist of one or more active ingredients , such as

Process for the preparation of these preparations.

The active substances should be present in these preparations in a concentration of 0.1 to 99.5% by weight, preferably 0.5 to 95% by weight, of the total mixture.

In addition to the active ingredients, the pharmaceutical preparations can also contain other pharmaceutical active ingredients.

The pharmaceutical preparations listed above can be prepared in a conventional manner by known methods, for example using the auxiliary agent or excipients.

In general, it has proven to be advantageous to use the active ingredient (s) in total amounts of about 0.01 to about 100 mg / kg, preferably in total amounts of about 1 mg / kg to 50 mg kg body weight per 24 hours, optionally in the form of several individual doses to deliver the desired result. However, it may be advantageous to deviate from the amounts mentioned, depending on the type and body weight of the object being treated, on the individual behavior towards the medication, the type and severity of the disease, the type of preparation and application, and the Time or interval at which the administration takes place.

Key for the DC solvent mixtures:

a) Ammonia MeOH / CHCl ₃ / AcOEt / n-hexane 1: 10: 100: 1.7: 3 b) Toluene / AcOEt 10: 1 c) Toluene / AcOEt 3: 1 d) Toluene / AcOEt 1: 1

Manufacturing examples

example 1

(Phenothiazine-10-yl) acetic acid-N, N-diethylamide

29.9 g (150 mmol) of phenothiazine are added in portions in 400 ml of dimethylformamide under nitrogen at 25 ° C. with a total of 3.9 g (160 mmol) of sodium hydride. After 30 min. After stirring, 25.0 g (160 mmol) of 2-chloro-N, N'-diethylacetamide (97%) in 50 ml of dimethylformamide are added dropwise within 30 minutes. After stirring overnight at 25 ° C., the mixture is poured onto ice and extracted with dichloromethane. The organic phase is washed twice with brine, dried over anhydrous sodium sulfate and in

Vacuum concentrated. The residue is chromatographed on 1000 g of silica gel using toluene / ethyl acetate (gradient) and gives 18.8 g of colorless crystals. Mp 129-130 ° C (from dichloromethane diethyl ether).

Example 2

Phenothiazine-10-carboxylic acid-N, N-di-n-butylamide

5.3 g (20 mmol) of phenothiazine-10-carboxylic acid chloride are mixed in succession in 80 ml of dichloromethane at 0 ° C with 2.6 g (20 mmol) of di-n-butylamine and 2.8 g (20 mmol) of triethylamine, and 72 h at 25 ° C stirred. The The reaction solution is mixed with 1N hydrochloric acid, then washed with water, dried over anhydrous sodium sulfate and evaporated in vacuo. The residue is chromatographed on silica gel (flash chromatography) and gives 4.5 g (63%) of colorless crystals. 42-43 ° C (from petroleum ether, bp 40 ° C).

Example 3

3- (phenothiazine-10-yl) propionic acid-N-n-butylamide

4.2 g (150 mmol) of methyl 3 - (phenothiazin-10-yl) propionate and 2.2 g (30 mmol) of n-butylamine are heated at 100 ° C. under nitrogen for 18 h. The reaction product taken up in 60 ml of methylene chloride is washed with 1 N hydrochloric acid and then with water, dried over anhydrous sodium sulfate and evaporated in vacuo. The residue (4.9 g) is filtered through silica gel (flash chromatography). 4.8 g (98% of theory) of colorless crystals are obtained. M.p. 106-107 ° C (from dichloromethane / petroleum ether).

Example 4

3 - (2-chlorophenothiazine-10-yl) propionic acid-N-n-butylamide

To 5.1 g (16 mmol) of 3- (2-chlorophenothiazin-10-yl) propionic acid chloride in 100 ml of dichloromethane are added 1.2 g (16 mmol) of n-butylamine and 1.6 g in succession with ice cooling and stirring (2.2 ml, 16 mmol) triethylamine added. After stirring for 20 h at 25 ° C., the reaction solution is introduced into ice water and made alkaline with ammonia water (pH 9). Extracting with dichloromethane, washing the dichloromethane extracts with water and then drying over anhydrous sodium sulfate yield, after evaporation in vacuo and chromatography of the residue on silica gel (100 g) with toluene / ethyl acetate, 5.3 g of crystalline product. Crystallization from dichloromethane / petroleum ether gives 4.2 g (36% of theory) of the title compound. Mp 89-91 ° C.

The compounds listed in Tables 1, 2 and 3 are prepared in analogy to the production instructions listed above.

Table 1:

Claims

1. Use of N-substituted phenothiazines of the general formula 0 ⁾

in which

R ¹ for a radical of the formula - (CH ₂ ) _a -CO-R ⁶ , - (CH ₂ ) _a -CO-NR ⁷ R ⁸ or

- (CH ₂ ) _b -R ⁹ ,

wherein

a represents a number 0, 1 or 2,

b represents a number 1 or 2,

R ⁶ denotes hydrogen or straight-chain or branched alkoxy or alkyl each having up to 6 carbon atoms, the latter being able to be substituted by halogen or hydroxy,

R ⁷ denotes hydrogen or straight-chain or branched alkyl having up to 6 carbon atoms, which is optionally substituted by halogen,

R ^{8 is} hydrogen, cycloalkyl having 3 to 6 coblene atoms,

Means pyridyl, phenyl, amino or straight-chain or branched alkyl having up to 6 carbon atoms, which is optionally substituted by hydroxy or pyridyl, or

and their salts

for the manufacture of medicinal products for the treatment of diseases of the CNS.

2. Use of N-substituted phenothiazines of the formula (I) according to Claim 1, in which

wherein

a represents a number 0, 1 or 2,

b represents a number 1 or 2,

R ⁶ denotes hydrogen or straight-chain or branched alkoxy or alkyl each having up to 4 carbon atoms, the latter being able to be substituted by fluorine, chlorine or hydroxy, R is hydrogen or straight-chain or branched alkyl having up to 4 carbon atoms, which is optionally substituted by chlorine,

R ⁸ denotes hydrogen, pyridyl, phenyl, amino, cyclopropyl, cyclopentyl, cyclohexyl or straight-chain or branched alkyl having up to 4 carbon atoms, which is optionally substituted by hydroxy or pyridyl,

or

R ³ and R ^{4 represent} hydrogen,

and their salts,

for the manufacture of medicaments for the treatment of diseases of the

CNS.

3. Use of N-substituted phenothiazines of the formula (I) according to claim 1, wherein

woπn a represents a number 0, 1 or 2,

b represents a number 1 or 2,

R ^{6 is} hydrogen or straight-chain or branched alkoxy or

Alkyl with up to 4 carbon atoms each, the latter being substituted by fluorine, chlorine or hydroxy,

R ^{8 is} hydrogen, pyridyl, phenyl, amino, cyclopropyl, cyclopentyl, cyclohexyl or straight-chain or branched

Means alkyl with up to 4 carbon atoms, which is optionally substituted by hydroxy or pyridyl,

or

R ³ and R ^{4 represent} hydrogen,

and their salts,

for the manufacture of medicinal products for combating diseases of the CNS. 4. Use according to claim 1 to 3 for the manufacture of medicaments for the treatment of central degenerative diseases.

5. Use according to claim 1 to 3 for the manufacture of medicaments for the treatment of brain disorders in old age.

6. Use according to claim 1 to 3 for the manufacture of medicaments for the treatment and prophylaxis of the consequences of cerebral circulatory disorders.

7. Use according to claim 1 to 3 for the manufacture of medicaments for

Treatment of depression and psychosis.

8. N-substituted phenothiazines of the series

- Phenothiazine-10-carboxylic acid N- (pyrid-4-yl) amide

Phenothiazine 10-carboxylic acid (N-methyl-N-phenyl) amide phenothiazine 10-carboxylic acid (N, N-di-n-butyl) amide phenothiazine 10-carboxylic acid (N-cyclohexyl-N-methyl) amide 3- (2-chlorophenothiazin-10-yl) propionic acid-N-ethylamide - 3- (2-chlorophenothiazin-10-yl) propionic acid (N-propyl) amide

3- (2-chlorophenothiazin-10-yl) propionic acid (N- (pyridin-4-ylmethyl)) amide

3- (phenothiazine-10-yl) propionic acid (N-propyl) amide

Phenothiazine-10-acetic acid-diethylamide - phenothiazine-10-carboxylic acid pyrolianimide

Phenothiazine-10-carboxylic acid-morpholineimide (phenothiazine-10-yl) -carboxylic acid-azacy cloheptylimide (phenothiazine-10-yl) -acetic acid-n-propylamide (phenothiazine-10-yl) -acetic acid-ethylamide - (phenothiazine-10-yl ) -acetic acid-di-n-propylamide

Phenothiazine-10-propynoic acid-Nn-butylamide 4-chloro-1 - (2-chloro-orphenothiazine-10-yl) butane-1-one 4-chloro-1 - (phenothiazine-10-yl) butane-1-one phenothiazine - 10-acetic acid-n-butylamide - 3- (2-chlorophenothiazin-10-yl) -Nn-butylamide. Process for the preparation of N-substituted phenothiazines according to Claim 8, characterized in that

Phenothiazine directly with the corresponding acids, esters or amides in inert solvents and in the presence of a base, if appropriate under a protective gas atmosphere

or the corresponding phenothiazinoyl chlorides are reacted with amines in inert solvents, if appropriate in the presence of a further base.

10. Medicament containing at least one N-substituted phenothiazine according to claim 8 and conventional formulation auxiliaries.